PYC Therapeutics (PYC) H2 2026 earnings summary

Executive summary

• Achieved a transformational year, advancing four key drug development programs targeting major unmet medical needs in genetic diseases.

• Strengthened balance sheet with ~$600 million capital raise, extending funding runway into 2030 and attracting leading global life sciences investors.

• Focused on delivering critical human safety and efficacy data to support progression into registrational trials.

Financial highlights

• Total income increased by $13.5 million to $39.7 million, driven by higher interest income and R&D tax incentive receipts.

• Net loss for the year ended 30 June 2026 was $43.8 million, an improvement from $51.0 million in the prior year.

• Research and development expenditure rose to $74.0 million (FY25: $70.1 million), reflecting continued investment in clinical and pre-clinical programs.

• Cash, cash equivalents, financial assets, and R&D tax receivables totaled $696 million at year end.

• Net assets increased to $693.3 million (2025: $170.0 million), with total assets of $708.5 million and liabilities of $15.2 million.

Outlook and guidance

• Expecting key clinical data readouts across all four programs over the next 12–24 months, which will inform further development and commercial options.

• Funding secured to support operations and clinical milestones through 2030.

• Anticipates progression into registrational trials and potential expansion into additional indications.